Latest Strategic Placements News

FortifAI has emerged from its first year as an AI infrastructure company with $20.4 million in cash, but a $29 million statutory loss and sharply lower gaming revenue. The company now needs to turn NOL8’s early testing and partnerships into commercial adoption before its cash-backed growth strategy faces a harder test.

Javelin Minerals is pursuing an all-scrip takeover by FirstAU after its planned Eureka production partnership with MEGA Resources was terminated over regional processing constraints. The company reported a $2.69 million FY2026 loss, $3.92 million in cash and an auditor warning that further funding is required.

Lincoln Minerals has moved Minbrie’s Eagle Ridge prospect towards diamond drilling after air core work supported its geological model. But the ASX-listed explorer remains loss-making, cash-burning and dependent on further funding to continue its exploration program.

Stellar Resources has lifted its Heemskirk tin resource to 115.3kt of contained tin while technical studies move toward a prefeasibility study outcome. The company is better funded, but remains pre-revenue and faces the usual capital, permitting and execution hurdles of mine development.

Lion Rock Minerals has reported high-grade rutile and rare-earth results from its 80%-owned Minta project in Cameroon, including up to 4.54% TREO over 2.3 metres. But the exploration story arrives alongside a larger loss, $7.93 million in operating cash outflow and an auditor-flagged material uncertainty over future funding.

Gold Hydrogen has advanced Ramsay drilling, testing and commercial studies, but its annual report carries a material uncertainty over the company’s ability to continue as a going concern. The pre-revenue explorer ended FY2026 with $9.42 million in cash after spending heavily on exploration.

Maronan Metals has marked a transformative year with a positive Preliminary Economic Assessment, grant of a key Mineral Development Licence, and two capital raises totaling nearly A$40 million, positioning the company for accelerated development of its Queensland silver-lead and copper-gold project.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Australian Dairy Nutritionals reported a 47% reduction in net loss for FY26, driven by a 66% revenue jump in its nutritional powders segment, which now makes up 70% of total revenue.

Jcurve Solutions (ASX:JCS) posted a significant financial turnaround in FY2026, with revenue climbing 16.3% to $13.28 million and normalised EBITDA more than doubling to $1.88 million, underpinned by disciplined cost control and recurring revenue growth.

Auris Minerals cut its annual loss to $604,506 and is gearing up for key drilling at Morck Well while progressing mining studies at Forrest, backed by a $3.05 million cash buffer.